The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Items 301–400 of 1,000
Clark, R. V., Walker, A. C., Andrews, S. M., Turnbull, P., Wald, J. A., & Magee, M. H. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13316 · Cited by 64
Anabolic-Androgenic Steroid Use in Sports, Health, and Society
Bhasin, S., Hatfield, D. L., Hoffman, J. R., Kraemer, W. J., LaBotz, M., Phillips, S. M., & Ratamess, N. A. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002670 · Cited by 63
Self-citationBendayan, M., Bibas, L., Levi, M., Mullie, L., Forman, D. E., & Afilalo, J. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.07.005 · Cited by 63
Aging Biology and Novel Targets for Drug Discovery
Couteur, D. G. L., McLachlan, A. J., Quinn, R. J., Simpson, S. J., & de Cabo, R. (2011) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr095 · Cited by 61
Testosterone treatment in the aging male: myth or reality?
Nigro, N., & Christ‐Crain, M. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13539 · Cited by 59
Practical Use of Pharmacotherapy for Obesity
Igel, L. I., Kumar, R. B., Saunders, K. H., & Aronne, L. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.049 · Cited by 59
Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study
Pickering, A. N., Hamm, M., Dawdani, A., Hanlon, J. T., Thorpe, C. T., Gellad, W. F., & Radomski, T. R. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16370 · Cited by 61
Parahiba, S. M., Ribeiro, É. C. T., Corrêa, C., Bieger, P., Perry, I. D. S., & Souza, G. C. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111106 · Cited by 59
Expression of androgen receptor target genes in skeletal muscle
Rana, K., Lee, N. K. L., Zajac, J. D., & MacLean, H. E. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122861 · Cited by 59
Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study
Etminan, M., Skeldon, S., Goldenberg, S. L., Carleton, B., & Brophy, J. M. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1534 · Cited by 59
Gencer, B., Bonomi, M., Adorni, M. P., Sirtori, C. R., Mach, F., & Ruscica, M. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09628-2 · Cited by 58
Saad, F., Haider, K. S., Yassin, A. A., Doros, G. D., Rosano, G. M. C., & Haider, A. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s108947 · Cited by 58
Testosterone Deficiency: A Review and Comparison of Current Guidelines
Kwong, J. C. C., Krakowsky, Y., & Grober, E. D. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.03.262 · Cited by 58
Low testosterone in men predicts impaired arterial elasticity and microvascular function
Corrigan, F. E., Mheid, I. A., Eapen, D. J., Hayek, S. S., Sher, S., Martin, G. S., & Quyyumi, A. A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.065 · Cited by 57
Mechanism and novel therapeutic approaches to wasting in chronic disease
Ebner, N., Springer, J., Kalantar‐Zadeh, K., Lainščak, M., Doehner, W., Anker, S. D., & von Haehling, S. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.03.014 · Cited by 60
Traish, A. M., & Zitzmann, M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9323-2 · Cited by 57
Passey, S. L., Hansen, M. J., Bozinovski, S., McDonald, C. F., Holland, A. E., & Vlahos, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.013 · Cited by 57
Basaria, S. S., Davda, M. N., Travison, T. G., Ulloor, J., Singh, R., & Bhasin, S. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls138 · Cited by 56
Self-citationSakakibara, I., Yanagihara, Y., Himori, K., Yamada, T., Sakai, H., Sawada, Y., Takahashi, H., Saeki, N., Hirakawa, H., Yokoyama, A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102303 · Cited by 60
Testosterone, Hypogonadism, and Heart Failure
Lodovico, E. D., Facondo, P., Delbarba, A., Pezzaioli, L. C., Maffezzoni, F., Cappelli, C., & Ferlin, A. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008755 · Cited by 57
Effects of testosterone on the Q-T Interval in older men and older women with chronic heart failure
Schwartz, J. B., Volterrani, M., Caminiti, G., Marazzi, G., Fini, M., Rosano, G. M. C., & Iellamo, F. (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2011.01163.x · Cited by 56
Walsh, J., & Eastell, R. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.171 · Cited by 57
Testosterone boosts physical activity in male mice via dopaminergic pathways
Jardí, F., Laurent, M. R., Kim, N., Khalil, R., Bundel, D. D., Eeckhaut, A. V., Helleputte, L. V., Deboel, L., Dubois, V., Schollaert, D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-19104-0 · Cited by 56
Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System
Ueda, K., Fukuma, N., Adachi, Y., Numata, G., Tokiwa, H., Toyoda, M., Otani, A., Hashimoto, M., Liu, P., & Takimoto, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738218 · Cited by 57
Undertreatment of Erectile Dysfunction: Claims Analysis of 6.2 Million Patients
Frederick, L. R., Çakır, Ö. O., Arora, H., Helfand, B. T., & McVary, K. T. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12647 · Cited by 55
Current topics in testosterone replacement of hypogonadal men
Nieschlag, E. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.008 · Cited by 55
Glueck, C. J., Goldenberg, N., Budhani, S., Lotner, D., Abuchaibe, C., Gowda, M., Nayar, T., Khan, N., & Wang, P. (2011) · Translational research · doi:10.1016/j.trsl.2011.06.003 · Cited by 55
EMAS position statement: Testosterone replacement therapy in the aging male
Dimopoulou, C., Ceauşu, I., Depypere, H. T., Lambrinoudaki, I. V., Mueck, A. O., Pérez-López, F. R., Rees, M., van der Schouw, Y. T., Senturk, L. M., Simonsini, T., et al. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.11.003 · Cited by 55
Brand, J. S., Wareham, N. J., Dowsett, M., Folkerd, E. J., van der Schouw, Y. T., Luben, R., & Khaw, K. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03951.x · Cited by 55
Adverse Events Associated with Testosterone Administration
Weikert, C., Pischon, T., & Weikert, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009326 · Cited by 55
Haring, R., Nauck, M. A., Völzke, H., Endlich, K., Lendeckel, U., Friedrich, N., Dörr, M., Rettig, R., Kroemer, H. K., & Wallaschofski, H. (2011) · American Journal of Nephrology · doi:10.1159/000324562 · Cited by 54
Westley, C. J., AMDUR, R. L., & Irwig, M. S. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12937 · Cited by 54
Haring, R., Teumer, A., Völker, U., Dörr, M., Nauck, M., Biffar, R., Völzke, H., Baumeister, S., & Wallaschofski, H. (2012) · Andrology · doi:10.1111/j.2047-2927.2012.00002.x · Cited by 54
Androgen actions on endothelium functions and cardiovascular diseases.
Cai, J., Wen, J., Jiang, W., Lin, J., Yuan, H., & Zhu, Y. (2016) · PubMed · doi:10.11909/j.issn.1671-5411.2016.02.003 · Cited by 54
Budoff, M. J., Lakshmanan, S., Toth, P. P., Hecht, H. S., Shaw, L. J., Maron, D. J., Michos, E. D., Williams, K. A., Sr., Nasir, K., Choi, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100318 · Cited by 54
Do low testosterone levels contribute to ill-health during male ageing?
Yeap, B. B., de Araújo, A. B., & Wittert, G. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2012.725461 · Cited by 53
Rochira, V., Diazzi, C., Santi, D., Brigante, G., Ansaloni, A., Decaroli, M. C., Vincentis, S. D., Stentarelli, C., Zona, S., & Guaraldi, G. (2015) · Andrology · doi:10.1111/andr.310 · Cited by 54
Ho, C. C. K., Tong, S. F., Low, W. Y., Ng, C. J., Khoo, E. M., Lee, V. K. M., Zainuddin, Z. M., & Tan, H. M. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10755.x · Cited by 53
Maggi, M., Wu, F. C. W., Jones, T. H., Jackson, G., Behre, H. M., Hackett, G. I., Martín‐Morales, A., Balercia, G., Dobs, A. S., Arver, S., et al. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12876 · Cited by 52
Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.
Cattabiani, C., Basaria, S. S., Ceda, G. P., Luci, M., Vignali, A., Lauretani, F., Valenti, G., Volpi, R., & Maggio, M. G. (2012) · PubMed · doi:10.3275/8061 · Cited by 52
Self-citationAndrogen Physiology, Pharmacology, and Abuse
Handelsman, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00138-4 · Cited by 54
Vicencio, J. M., Estrada, M., Galvis, D. M. S., Bravo, R., Contreras‐Ferrat, A. E., Rotter, D., Szabadkai, G., Hill, J. A., Rothermel, B. A., Jaimovich, E., et al. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711795445880 · Cited by 52
Heart Failure as a Risk Factor for Osteoporosis and Fractures
Aluoch, A. O., Jessee, R. C., Habal, H., Garcia-Rosell, M., Shah, R., Reed, G. L., & Carbone, L. D. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0115-2 · Cited by 53
Ascertainment of Testosterone Prescribing Practices in the VA
Jasuja, G. K., Bhasin, S., Reisman, J. I., Berlowitz, D. R., & Rose, A. J. (2015) · Medical Care · doi:10.1097/mlr.0000000000000398 · Cited by 51
Self-citationTestosterone and Cardiovascular Risk in Men
Kelly, D. M., & Jones, T. H. (2014) · Frontiers of hormone research · doi:10.1159/000360553 · Cited by 52
Corona, G., Rastrelli, G., Monami, M., Melani, C., Balzi, D., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02292.x · Cited by 51
Characteristics of Compensated Hypogonadism in Patients with Sexual Dysfunction
Corona, G., Maseroli, E., Rastrelli, G., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12549 · Cited by 51
Farias, J. M., Tinetti, M., Khoury, M. C., & Umpierrez, G. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2585 · Cited by 51
Adverse health effects of testosterone deficiency (TD) in men
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.010 · Cited by 51
Osteoporosis in older men: Recent advances in pathophysiology and treatment
Laurent, M. R., Gielen, E., Claessens, F., Boonen, S., & Vanderschueren, D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.04.010 · Cited by 51
Tan, W. S., Low, W. Y., Ng, C. J., Tan, W. K., Tong, S. F., Ho, C. C. K., Khoo, E. M., Lee, G., Lee, B. C., Lee, V., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12037 · Cited by 51
Testosterone Replacement Therapy and Cardiovascular Risk: A Review
Giovanni Corona, G., Rastrelli, G., Maseroli, E., Sforza, A., & Maggi, M. (2015) · The World Journal of Men s Health · doi:10.5534/wjmh.2015.33.3.130 · Cited by 51
Testosterone Therapy: Review of Clinical Applications.
Petering, R. C., & Brooks, N. A. (2017) · PubMed · Cited by 51
Marketing and Testosterone Treatment in the USA: A Systematic Review
Bandari, J., Ayyash, O. M., Emery, S., Wessel, C. B., & Davies, B. J. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.10.016 · Cited by 51
Kirby, M., Hackett, G. I., & Ramachandran, S. (2019) · European Cardiology Review · doi:10.15420/ecr.2019.13.1 · Cited by 53
Chung, J., Brown, S., Chen, H., Liu, J., Papadopoulos, V., & Zirkin, B. R. (2019) · Biology of Reproduction · doi:10.1093/biolre/ioz174 · Cited by 51
Testosterone induces leucocyte migration by NADPH oxidase-driven ROS- and COX2-dependent mechanisms
Chignalia, A. Z., Oliveira, M. A., Debbas, V., Dull, R. O., Laurindo, F. R. M., Touyz, R. M., de Carvalho, M. H. C., Fortes, Z. B., & Tostes, R. C. (2015) · Clinical Science · doi:10.1042/cs20140548 · Cited by 51
Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease
Romejko, K., Rymarz, A., Sadownik, H., & Niemczyk, S. (2022) · Nutrients · doi:10.3390/nu14163438 · Cited by 52
Cunningham, R. L., Singh, M., O’Bryant, S. E., Hall, J. R., & Barber, R. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131994 · Cited by 50
Stanworth, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.03969.x · Cited by 50
Elevated LH predicts ischaemic heart disease events in older men: the Health in Men Study
Hyde, Z., Norman, P. E., Flicker, L. A., Hankey, G. J., McCaul, K. A., Almeida, O. P., Chubb, S. A. P., & Yeap, B. B. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1063 · Cited by 50
Klinefelter syndrome and testosterone treatment: a national cohort study on thrombosis risk
Chang, S., Christiansen, C. F., Bojesen, A., Juul, S., Münster, A. B., & Gravholt, C. H. (2020) · Endocrine Connections · doi:10.1530/ec-19-0433 · Cited by 50
Monnerat, G., Seara, F. D. A. C., Evaristo, J. A. M., Carneiro, G. R. A., Evaristo, G. P. C., Domont, G. B., Nascimento, J. H. M., Mill, J. G., Nogueira, F. C. S., & de Carvalho, A. C. C. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.05.005 · Cited by 49
Transdermal delivery of testosterone
Hadgraft, J., & Lane, M. E. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.015 · Cited by 49
Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus
Kamenov, Z. A., Parapunova, R., & Georgieva, R. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.11.001 · Cited by 49
Laubach, J. P., Moslehi, J. J., Francis, S. A., Miguel, J. F. S., Sonneveld, P., Orlowski, R. Z., Moreau, P., Rosiñol, L., Faber, E. A., Voorhees, P. M., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14708 · Cited by 49
Traish, A. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_22 · Cited by 50
Garratt, M., Leander, D. C., Pifer, K., Bower, B., Herrera, J. J., Day, S. M., Fiehn, O., Brooks, S. V., & Miller, R. A. (2019) · Aging Cell · doi:10.1111/acel.12920 · Cited by 51
Involvement of p38 MAPK in Leydig cell aging and age-related decline in testosterone
Luo, D., Qi, X., Xu, X., Yang, L., Yu, C., & Guan, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1088249 · Cited by 48
Klinefelter syndrome and medical treatment: hypogonadism and beyond
Chang, S., Skakkebaek, A. H., & Gravholt, C. H. (2015) · HORMONES · doi:10.14310/horm.2002.1622 · Cited by 50
Jayasena, C. N., Alkaabi, F., Liebers, C. S., Handley, T. J., Franks, S., & Dhillo, W. S. (2018) · Clinical Endocrinology · doi:10.1111/cen.13906 · Cited by 51
Loo, S. Y., Azoulay, L., Nie, R., Dell’Aniello, S., Yu, O. H. Y., & Renoux, C. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.03.022 · Cited by 48
Hormonal changes and their impact on cognition and mental health of ageing men
Yeap, B. B. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.015 · Cited by 49
Is Testosterone Replacement Therapy in Older Men Effective and Safe?
Yabluchanskiy, A., & Tsitouras, P. D. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00716-2 · Cited by 47
Safi, R., Wardell, S. E., Watkinson, P., Qin, X., Lee, M., Park, S., Krebs, T., Dolan, E. L., Blattler, A., Tsuji, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52032-y · Cited by 47
The 20-Year Public Health Impact and Direct Cost of Testosterone Deficiency in U.S. Men
Moskovic, D. J., de Araújo, A. B., Lipshultz, L. I., & Khera, M. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02944.x · Cited by 47
Androgens and stroke: Good, bad or indifferent?
Quillinan, N., Deng, G., Grewal, H., & Herson, P. S. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.02.004 · Cited by 47
The effect of androgens on lipids
Monroe, A. K., & Dobs, A. S. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835edb71 · Cited by 47
The safety of available treatments of male hypogonadism in organic and functional hypogonadism
Corona, G., Rastrelli, G., Reisman, Y., Sforza, A., & Maggi, M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1424831 · Cited by 47
Ayele, H. T., Brunetti, V. C., Renoux, C., Tagalakis, V., & Filion, K. B. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.029 · Cited by 48
An update on male hypogonadism therapy
Surampudi, P. N., Swerdloff, R. S., & Wang, C. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.913022 · Cited by 46
Corona, G., Rastrelli, G., Maseroli, E., Fralassi, N., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2014) · Andrology · doi:10.1111/j.2047-2927.2014.00241.x · Cited by 46
Nilsson, P. M., Viigimaa, M., Giwercman, A., & Cífková, R. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01036-2 · Cited by 51
Pelusi, C., Giagulli, V. A., Baccini, M., Fanelli, F., Mezzullo, M., Fazzini, A., Bianchi, N., Carbone, M. D., De Pergola, G., Mastroroberto, M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183369 · Cited by 45
Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.10.001 · Cited by 46
Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity
Fernandez-Garcia, J.-C., Molina‐Vega, M., Muñoz-Garach, A., Damas-Fuentes, M., & Tinahones, F. J. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_44_18 · Cited by 49
Testosterone Replacement Therapy in Hypogonadal Men
Wang, C., & Swerdloff, R. S. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.005 · Cited by 48
Standardization of Hormonal Assays for the 21st Century
Wartofsky, L., & Handelsman, D. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2369 · Cited by 45
Jasuja, G. K., Bhasin, S., Reisman, J. I., Hanlon, J. T., Miller, D. R., Morreale, A. P., Pogach, L. M., Cunningham, F. E., Park, A., Berlowitz, D. R., et al. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3940-7 · Cited by 44
Self-citationThe roles of sex hormones in the pathophysiology of age‐related sarcopenia and frailty
Hosoi, T., Yakabe, M., Hashimoto, S., Akishita, M., & Ogawa, S. (2024) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12569 · Cited by 46
Androgenic hormones and aging — The link with female sexual function
Davison, S. L., & Davis, S. R. (2011) · Hormones and Behavior · doi:10.1016/j.yhbeh.2010.12.013 · Cited by 45
Andropause – lessons from the European Male Ageing Study
Huhtaniemi, I. T. (2014) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.03.005 · Cited by 44
Davis, D., Ruiz, A. L., Yanes, L. L., Iliescu, R., Yuan, K., Moulana, M., Racusen, L. C., & Reckelhoff, J. F. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.180943 · Cited by 44
Testosterone and cardiovascular disease risk
Yeap, B. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000161 · Cited by 44
Pharmacological management of late-onset hypogonadism
Rastrelli, G., Maggi, M., & Corona, G. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445969 · Cited by 46
Yeap, B. B., & Wu, F. C. W. (2018) · Clinical Endocrinology · doi:10.1111/cen.13888 · Cited by 45
Blick, G., Khera, M., Bhattacharya, R. K., Nguyen, D., Kushner, H., & Miner, M. M. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01368.x · Cited by 45
Evolution of Guidelines for Testosterone Replacement Therapy
Park, H. J., Ahn, S. T., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030410 · Cited by 44
Interventions targeting geriatric frailty: A systemic review
Lee, P.-H., Lee, Y., & Chan, D. (2012) · Journal of Clinical Gerontology and Geriatrics · doi:10.1016/j.jcgg.2012.04.001 · Cited by 43
Integrated Therapies for Osteoporosis and Sarcopenia: From Signaling Pathways to Clinical Trials
Girgis, C. M. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9956-x · Cited by 43
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
